

**METRONOMIC ANTI-ANGIOGENIC CHEMOTHERAPY:****FROM BENCH TO BEDSIDE**

METRONOMIC CHEMOTHERAPY – THE USE OF RELATIVELY NON-TOXIC LOWER DOSES OF CONVENTIONAL CHEMOTHERAPY DRUGS ADMINISTERED AT CLOSE, REGULAR INTERVALS WITHOUT ANY PROLONGED BREAK PERIODS – IS ATTRACTING INCREASING INTEREST AS A SUPPLEMENT OR ALTERNATIVE TO CONVENTIONAL CHEMOTHERAPY REGIMENS. CURRENTLY THERE ARE AT LEAST FIVE RANDOMIZED PHASE III CLINICAL TRIALS UNDERWAY AROUND THE WORLD EVALUATING THE TREATMENT CONCEPT. A NUMBER OF THESE TRIALS AS WELL AS MANY PHASE II TRIALS INVOLVE COMBINATION WITH TARGETED BIOLOGIC AGENTS, ESPECIALLY ANTIANGIOGENIC DRUGS. THE PURPOSE OF THIS WORKSHOP IS TO BRING TOGETHER A SMALL GROUP OF DEDICATED CLINICAL AND BASIC RESEARCH INVESTIGATORS TO DISCUSS THE LATEST CLINICAL AND PRECLINICAL DEVELOPMENTS IN THE FIELD WITH THE GOAL OF UTILIZING METRONOMIC CHEMOTHERAPY MORE EFFECTIVELY IN BOTH PEDIATRIC AND ADULT ONCOLOGY PATIENTS.

**Program****22-23 March 2012 Dan Carmel Hotel, Haifa- Israel****Day 1 22.3.2012**

- 9.30-10.00 **Welcome and Introduction**
- 10.00-10.30 *RESOLVIN the Role of Metronomic Therapy in Cancer - The Path Through Inflammation.*  
Mark Kieran - Boston, USA
- 10.30-11.00 *Biomarker-driven selection of breast cancer patients candidate to combinatorial treatment using metronomic chemotherapy and antiangiogenic drugs: The Milan experience, 2001-2011.*  
Francesco Bertolini - Milan, Italy
- 11.00-11.20 **Coffee Break and Exhibition**
- 11.20-12.00 Keynote talk: *Metronomic chemotherapy-based therapies evaluated in models of advanced metastatic disease: rationale and (promising) results.*  
Robert S. Kerbel - Toronto, Canada
- 12.00-12.30 *Aspects of combinatorial treatment strategy: metronomic chemotherapy in combination with targeted drugs blocking VEGF pathway.*  
Yuval Shaked - Haifa, Israel
- 12.30 -13.00 *Metronomic Therapy: Is it really a New Paradigm for Chemotherapy?*  
Barton Kamen - New Jersey, USA
- 13.00-14.00 **Refreshments and Exhibition**
- 14.00-14.30 *Novel use of beta-blockers to promote the anti-angiogenic activity and increase the efficacy of chemotherapy in drug-refractory cancers.*  
Eddy Pasquier - Sydney, Australia
- 14.30-15.00 *Metronomic chemotherapy in children: aspects of therapy in leukemia and solid tumors.*  
Nicolas Andre - Marseille, France
- 15.00-15.30 *Clinical experience with metronomic chemotherapy in pediatric oncology - six years with COMBAT and succeeding regimens.*  
Jaroslav Sterba - Brno, Czech Republic
- 15.30-16.00 *Metronomics: Slow and Steady Wins The Race!*  
Shripad Banavali - Mumbai, India

**Day 2 23.3.2012**

- 9.00-10.00 **Best Abstract Session**
- 10.00-12.00 Workshop Session – Adult and Pediatric:  
"Developing new clinical trials using metronomic chemotherapy with targeted drugs".
- 12.00 **Refreshments**

**Sponsors****RAPPAPORT INSTITUTE**

sanofi aventis





## Call for Abstracts

### **3<sup>rd</sup> Workshop on Metronomic Anti-Angiogenic Chemotherapy: From Bench to Bedside**

**22-23 March 2012  
Dan Carmel Hotel, Haifa - Israel**

Participants are most welcomed to submit their original abstracts on related fields of investigation to the workshop.

### **Free Registration**

#### **Instruction for Preparing Abstracts**

1. Abstracts must be typed in **ENGLISH** and saved in Microsoft Word format with body limited to one page.
2. The text should be **1.5 lines spaced** and written in point **size 12**, using **Times New Roman** font.
3. The author information should be bold in point size 12 and include the name of the presenting author of the abstract underline.

#### **General Policy**

- All abstracts must be submitted and be received on or before **February 15, 2012.**

- Abstracts must be submitted by email to:

**Valeria Miller**

**vmiller@tx.technion.ac.il**

- All abstracts will be reviewed by the scientific committee of the 3<sup>rd</sup> Metronomic Anti-Angiogenic Chemotherapy workshop, and the reviewing results will be announced by emailing a notice of acceptance/ rejection to corresponding author by **March 1, 2012.**

#### **Scientific Contact and Abstract Submission**

Valeria Miller

vmiller@tx.technion.ac.il

#### **Scientific committee**

- Yuval Shaked - Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
- Abraham Kuten – Rambam Health Care Campus, Haifa, Israel.
- Myriam Ben-Arush - Rambam Health Care Campus, Haifa, Israel.

#### **General Organization**

IMKnasim LTD.

Tel: +972-3-6081520

Fax: +972-3-6081522

Email: knasim@imknasim.co.il